TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Douglas S Hawkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.